First Amendment to Drug Product Production and Clinical Supply AgreementAltus Pharmaceuticals Inc. • August 8th, 2007 • Biological products, (no disgnostic substances)
This First Amendment (the “Amendment”) is entered into and effective as of June 25, 2007 (the “Amendment Date”) for the purpose of amending that certain Drug Product Production and Clinical Supply Agreement dated August 15, 2006 (the “Agreement”) by and between Altus Pharmaceuticals Inc., a Delaware corporation (“Altus”), and Althea Technologies, Inc., a Delaware corporation (“Althea”). Capitalized terms used but not otherwise defined herein shall have the meanings provided in the Agreement.
TERMINATION AGREEMENTTermination Agreement • August 8th, 2007 • Altus Pharmaceuticals Inc. • Biological products, (no disgnostic substances)
This Termination Agreement (the “Termination Agreement”) dated as of June 6, 2007 (the “Effective Date”) is an amendment to the Development, Commercialization and Marketing Agreement (the “Agreement”) dated as of December 23, 2002 by and between Altus Pharmaceuticals Inc. (the successor in interest to Altus Biologics Inc.), a Delaware corporation, with its principal office at 125 Sidney Street, Cambridge, MA 02139 USA (“ALTUS”) and Dr. Falk Pharma GmbH, a German corporation, with its principal office at Leinenweberstrasse 5, 79041 Freiberg Germany (“FALK”).
CONSENT TO SUBLEASELease Extension Agreement • August 8th, 2007 • Altus Pharmaceuticals Inc. • Biological products, (no disgnostic substances)
Pursuant to terms of the Prime Lease, you have asked for Landlord’s consent to the Sublease. This document (the “Consent”) evidences Landlord’s consent to the Sublease, effective as of the date hereof, upon the following express terms and conditions:
